Neuland Laboratories is investing $30 million in establishing a dedicated peptide manufacturing. Nicola Giubellina, PhD, Vice President, Head-CMS Business Development, Europe, Neuland Laboratories further detailed the expansion at the DCAT Member Company Announcement Forum at DCAT Week.  

At Neuland, a team of more than 50 expert scientists has been working on developing peptides to support the company’s two primary business verticals: Generic Drug Substances (GDS) and Custom Manufacturing Solutions (CMS). It technical capabilities in peptide synthesis, include solid-phase, liquid-phase, and hybrid-phase synthesis. Currently, the company is working on developing two-three complex generic peptide active pharmaceutical ingredients (APIs) for the GDS business. The team expects to reach a milestone this year (2025) that will enable them to start supporting generic formulators as well. The dedicated peptide facility will provided large-scale manufacturing of these peptides. 

The new facility will be equipped with advanced technology, including DSC automated systems, with a capacity of 6.37 KL. A modernized research and development facility will feature advanced equipment such as PeptiSystems (automated peptide synthesizers), tangential flow filtration, dynamic axial compression columns with diameters of 150 and 300 mm, quadrupole time-of-flight high-resolution mass spectrometers (QTOF-HRMS), continuous column purification systems, and stability indicators, including fluorescence spectroscopy and ion exchange columns. 

The facility’s building plan consists of four modules. The execution of Module I is scheduled to be completed by the first half of 2026 and achieve an initial capacity of tens of kilograms annually. The targeted scale-up across all four modules aims to reach a production capacity of over 100 kg.